SBIR-STTR Award

Scaling the Purification of Mycosporine-like Amino Acids to Replace Chemical Ultraviolet (UV) Filters and Protect Human and Environmental Health
Award last edited on: 9/5/2023

Sponsored Program
STTR
Awarding Agency
NSF
Total Award Amount
$1,162,595
Award Phase
2
Solicitation Topic Code
CT
Principal Investigator
David Smernoff

Company Information

Heliobiosys Inc

16363 Skyline Boulevard
Woodside, CA 94062
   (650) 722-2063
   N/A
   www.heliobiosys.com

Research Institution

Arizona State University

Phase I

Contract Number: 1940352
Start Date: 2/1/2020    Completed: 1/31/2021
Phase I year
2020
Phase I Amount
$225,000
The broader impact of this STTR Phase I project is to harvest a natural sunscreen for broader distribution. This project will use a group of fast-growing microorganisms that make these ingredients. The challenge will be to harvest enough of the material to make effective and affordable sunscreens. The problem is akin to trying to collect all the "needles in a haystack". New tools that incorporate reusable analogues to "magnets" for capturing and releasing the sunscreen compound will provide a novel way to get the material out of a complex mixture of broken open cells and into the sunscreens. There is a lack of genuinely non-toxic, environmentally safe sunscreens in the U.S. market today. Melanoma, the most common cancer in the U.S., is a deadly form of skin cancer directly attributable to sun damage to skin, and conventional sunscreens are under pressure because of human health concerns and possible impacts on coral reefs. This work will provide a new class of sunscreens safer for people and marine life. Unlocking the potential of this nature-designed sunscreen will improve human health and the environment.This STTR Phase I project will evaluate the technical feasibility of using aptamers (small nucleic acids) to isolate mycosporine-like amino acids (MAAs) from a complex mixture of compounds derived from cyanobacteria. Small molecules present challenges for aptamer development because they can be: difficult to immobilize, have multiple three-dimensional conformations, and few chemically distinguishing features. MAAs present unique challenges due to the similarity of their chemical structure with other cell lysate materials and wide variety of amino acid substitutions. This innovation entails the isolation and identification of the specific MAAs being produced, isolation of aptamers that are highly specific, and assessing process scalability. MAAs are not commercially available so reference standards will be derived from the culture broth. These materials will be utilized as targets in aptamer selection using a proprietary single-stranded DNA library of aptamer sequences to identify suitable candidates by next-generation sequencing and bioinformatics analysis. Those aptamer candidates will then be screened and evaluated using an affinity purification workflow and absorbance-based microplate assay. The end result of this work will be to establish if this is a robust and scalable affinity purification method for MAAs.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Phase II

Contract Number: 2222582
Start Date: 7/15/2023    Completed: 6/30/2025
Phase II year
2023
Phase II Amount
$937,595
The broader impact of this Small Business Technology Transfer (STTR) Phase II project will be to bring a new class of full spectrum Ultraviolet A and B (UVA and UVB) protective materials to market. Current chemical sunscreen ingredients raise health concerns for consumers. Additionally, some ingredients are banned for causing potential damage to coral reef ecosystems. Consumers increasingly want products that are safe for them and for the planet, and that are aesthetically pleasing. This project will explore ways to meet the growing demand for better sunscreen ingredients that are produced sustainably. This team will investigate methods to cost-effectively extract naturally-occurring materials from photosynthetic bacteria that can replace current chemical and mineral sunscreen active ingredients. These will also replace a significant portion of the UV filter ingredients. Sunscreens and other related products that might use these naturally occurring, safe, and effective ingredients will help people reduce UV damage to their skin and help reduce skin cancer (including deadly melanoma) and ameliorate skin aging. The project supports the US economy by creating jobs in the algae biotechnology field and in the cosmetic industry including testing, manufacturing, distribution, and sales. The technical innovation at the core of this proposal is to improve the yield and reduce the cost of extracting mycosporine-like amino acids (MAAs) from a complex mixture of compounds contained within cyanobacterial cells (or other MAA producing organisms). Small volumes of MAAs are currently obtained using expensive and hazardous solvents and expensive equipment. The innovation is focused on the use of synthetic nucleotides (aptamers) to selectively bind to the MAAs and purify them from a cell lysate. Mycosporine-like amino acids arose on early Earth to protect microbes from harmful UV radiation. Their prevalence and longevity substantiate their value in protecting cells from UV radiation and other forms of oxidative stress. Their presence in the Earth?s oceans for millennia speaks to their safety in marine ecosystems and suggests their safety for use on human skin; Safety will be verified using standard pre-clinical tests. Technical hurdles include the isolation and identification of the specific MAAs produced, identifying aptamers that are highly specific for the MAAs produced, determining MAA yield from several purification processes and assessing process scalability. These data will be compared to other isolation techniques (filtration and chromatography) to assess comparative yields and economic performance. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.